Compounds / Metabolic / Mazdutide

Mazdutide

Mazdutide (Dual GLP-1/Glucagon Receptor Agonist — IBI362)
MetabolicExtensively StudiedFDA: Not approved (Phase III; approved in...

Overview

Phase III trials. Extensively studied in Chinese population. MASH treatment arm particularly notable. Severe obesity management and metabolic syndrome improvement.

Mechanism of Action

Dual GLP-1R/glucagon receptor agonist. Developed by Innovent Biologics. GLP-1 effect on satiety + glucagon effect on energy expenditure and hepatic fat reduction. MASH (fatty liver) treatment potential.

Molecular Profile

Molecular weight
4,563.1 Da
Type
Oxyntomodulin analog with fatty acid conjugation
Length
33 amino acids

Key Research Findings

Dual GLP-1/glucagon; liver fat reduction (MASH); Phase III ongoing; severe obesity management.

Published Research

Lancet (2023)
Ji L et al. Efficacy and safety of mazdutide in Chinese patients with T2DM
View source

Related Metabolic Compounds

SemaglutideTirzepatideRetatrutideCagrilintideBioglutideAOD-9604
Clinical Guidance

Research data is not a treatment plan. If you are considering Mazdutide, the questions that matter are whether it suits your history, your labs and your goals. That is a conversation with a licensed physician, not a lookup.

Speak with a physician LATOM Wellness is a physician-led telehealth practice. Consultation only. No compound is sold on this site.
Running Mazdutide? Log doses and track your cycle.

Interactive tools for this compound:

Reconstitution calculator  ·  Full deep dive  ·  Peptide fundamentals